Literature DB >> 17154307

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.

Derek W Bartlett1, Mark E Davis.   

Abstract

Small interfering RNA (siRNA) molecules achieve sequence-specific gene silencing through the RNA interference (RNAi) mechanism. Here, live-cell and live-animal bioluminescent imaging (BLI) is used to directly compare luciferase knockdown by unmodified and nuclease-stabilized siRNAs in rapidly (HeLa) and slowly (CCD-1074Sk) dividing cells to reveal the impact of cell division and siRNA nuclease stability on the kinetics of siRNA-mediated gene silencing. Luciferase knockdown using unmodified siRNAs lasts approximately 1 week in HeLa cells and up to 1 month in CCD-1074Sk cells. There is a slight increase in the duration of luciferase knockdown by nuclease-stabilized siRNAs relative to unmodified siRNAs after cationic lipid transfection, but this difference is not observed after electroporation. In BALB/cJ mice, a fourfold increase in maximum luciferase knockdown is observed after hydrodynamic injection (HDI) of nuclease-stabilized siRNAs relative to unmodified siRNAs, yet the overall kinetics of the recovery after knockdown are nearly identical. By using a mathematical model of siRNA-mediated gene silencing, the trends observed in the experimental data can be duplicated by changing model parameters that affect the stability of the siRNAs before they reach the cytosolic compartment. Based on these findings, we hypothesize that the stabilization advantages of nuclease-stabilized siRNAs originate primarily from effects prior to and during internalization before the siRNAs can interact with the intracellular RNAi machinery. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154307     DOI: 10.1002/bit.21285

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  44 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

3.  Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

Authors:  Jonathan E Zuckerman; Chung Hang J Choi; Han Han; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

4.  Hydrolytic charge-reversal of PEGylated polyplexes enhances intracellular un-packaging and activity of siRNA.

Authors:  Thomas A Werfel; Corban Swain; Christopher E Nelson; Kameron V Kilchrist; Brian C Evans; Martina Miteva; Craig L Duvall
Journal:  J Biomed Mater Res A       Date:  2016-01-11       Impact factor: 4.396

Review 5.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

6.  A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.

Authors:  Marian Grade; Amanda B Hummon; Jordi Camps; Georg Emons; Melanie Spitzner; Jochen Gaedcke; Patrick Hoermann; Reinhard Ebner; Heinz Becker; Michael J Difilippantonio; B Michael Ghadimi; Tim Beissbarth; Natasha J Caplen; Thomas Ried
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

7.  Gold nanorod--siRNA induces efficient in vivo gene silencing in the rat hippocampus.

Authors:  Adela C Bonoiu; Earl J Bergey; Hong Ding; Rui Hu; Rajiv Kumar; Ken-Tye Yong; Paras N Prasad; Supriya Mahajan; Kelly E Picchione; Arin Bhattacharjee; Tracey A Ignatowski
Journal:  Nanomedicine (Lond)       Date:  2011-06       Impact factor: 5.307

8.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Authors:  Derek W Bartlett; Helen Su; Isabel J Hildebrandt; Wolfgang A Weber; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

Review 9.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

10.  RNAi revised--target mRNA-dependent enhancement of gene silencing.

Authors:  Simon Dornseifer; Sarah Willkomm; Rosel Kretschmer-Kazemi Far; Janine Liebschwager; Foteini Beltsiou; Kirsten Frank; Sandra D Laufer; Thomas Martinetz; Georg Sczakiel; Jens Christian Claussen; Tobias Restle
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.